Building Protection
Protection does not happen by chance. It is built through science, manufacturing, and long term commitment.
Behind every vaccine is a complex system of research, production, quality control, and distribution. Reliable protection depends on reliable manufacturing and the ability to deliver vaccines consistently, safely, and at scale.
Bogor, Indonesia
MAIN PRODUCTION HUB
Scale, Safety, and Compliance
Our 6-hectare integrated biopharma campus in Bogor, Indonesia, represents our commitment to global health standards. We operate with zero compromise on safety protocols and environmental responsibility.
Human Vaccine Facilities
Dedicated facilities for large-scale human vaccine production under cGMP standards.
Efficient Building
QC, QA, R&D, utilities, and admin on one site.
A-BSL3 Laboratories
Advanced Biosafety Level 3 labs designed for high-containment research and viral handling.
Animal House
Dedicated facilities testing to animal
Building Protection
End-to-EndBiopharmaceutical Capabilites
Biotis operates a complete value chain, from upstream to finished product release.
Built in Crisis, Proven in the Field
Our rapid mobilization during global health emergencies has solidified our role as a critical infrastructure partner. From 2020 to today, our milestones reflect unwavering growth.
- +Company incorporated
- +Research collaboration with Airlangga University to develop COVID-19 vaccine
- +Participated in the 'Vaksin Merah Putih' initiative
- +Initiated GMP Certification process
- +Non-clinical trials for the COVID-19 vaccine
- +Obtained a complete GMP Certification to produce vaccine
- +Received Halal Certificate for INAVAC
- +Received EUA (Emergency Use Authorization) for INAVAC from Indonesian FDA
- +Clinical trials for the COVID-19 vaccine
- +Launched INAVAC as the first and only human vaccine developed and produced in Indonesia
- +The Ministry of Health of The Republic of Indonesia started to purchase INAVAC from the Company
- +Received a permanent marketing license (NIE) for INAVAC from BPOM (Indonesian FDA)
- +Transfer technology agreement with Beijing Minhai Biotechnology Co., Ltd. (Minhai) (on April 2023)
- +Signed a partnership and technology transfer agreement with Biological E-India
- +Received marketing license for DPT-HB-Hib (Penta Valent) vaccine from BPOM
- +Signed a purchase contract for the Penta Valent Vaccine with the Ministry of Health of The Republic of Indonesia
- +Signed a MOU with ALPS Global, a Malaysian-based healthcare company, that specializes in stem cell therapy
- +Signed a partnership and technology transfer agreement with LG Chem of South Korea
- +The Ministry of Health of The Republic of Indonesia started to purchase PULMEERA from Biotis
- +Received a permanent marketing license (NIE) for PULMEERA from BPOM
- +Received a HALAL certificate for PULMEERA from Halal Product Assurance Body
Biotis Ecosystem
Biotis works closely with universities, technology partners, global biopharmaceutical companies, and government institutions to strengthen local capabilities and expand access to essential vaccines. These collaborations play a vital role in supporting innovation, ensuring quality, and building a resilient health system.
